These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
302 related articles for article (PubMed ID: 26872457)
1. Precision Medicine for Tobacco Dependence: Development and Validation of the Nicotine Metabolite Ratio. Allenby CE; Boylan KA; Lerman C; Falcone M J Neuroimmune Pharmacol; 2016 Sep; 11(3):471-83. PubMed ID: 26872457 [TBL] [Abstract][Full Text] [Related]
2. Nicotine Metabolism-informed Care for Smoking Cessation: A Pilot Precision RCT. Wells QS; Freiberg MS; Greevy RA; Tyndale RF; Kundu S; Duncan MS; King S; Abney L; Scoville E; Beaulieu DB; Gatskie V; Tindle HA Nicotine Tob Res; 2018 Nov; 20(12):1489-1496. PubMed ID: 29059367 [TBL] [Abstract][Full Text] [Related]
3. Rate of nicotine metabolism and smoking cessation outcomes in a community-based sample of treatment-seeking smokers. Kaufmann A; Hitsman B; Goelz PM; Veluz-Wilkins A; Blazekovic S; Powers L; Leone FT; Gariti P; Tyndale RF; Schnoll RA Addict Behav; 2015 Dec; 51():93-9. PubMed ID: 26240944 [TBL] [Abstract][Full Text] [Related]
4. The Nicotine Metabolite Ratio is Associated With Early Smoking Abstinence Even After Controlling for Factors That Influence the Nicotine Metabolite Ratio. Chenoweth MJ; Schnoll RA; Novalen M; Hawk LW; George TP; Cinciripini PM; Lerman C; Tyndale RF Nicotine Tob Res; 2016 Apr; 18(4):491-5. PubMed ID: 26069034 [TBL] [Abstract][Full Text] [Related]
5. Pathways to precision medicine in smoking cessation treatments. Chen LS; Horton A; Bierut L Neurosci Lett; 2018 Mar; 669():83-92. PubMed ID: 27208830 [TBL] [Abstract][Full Text] [Related]
6. The Use of the Nicotine Metabolite Ratio as a Biomarker to Personalize Smoking Cessation Treatment: Current Evidence and Future Directions. Siegel SD; Lerman C; Flitter A; Schnoll RA Cancer Prev Res (Phila); 2020 Mar; 13(3):261-272. PubMed ID: 32132120 [TBL] [Abstract][Full Text] [Related]
7. Interventions to reduce harm from continued tobacco use. Lindson-Hawley N; Hartmann-Boyce J; Fanshawe TR; Begh R; Farley A; Lancaster T Cochrane Database Syst Rev; 2016 Oct; 10(10):CD005231. PubMed ID: 27734465 [TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics factors influencing smoking cessation success; the importance of nicotine metabolism. Perez-Paramo YX; Lazarus P Expert Opin Drug Metab Toxicol; 2021 Mar; 17(3):333-349. PubMed ID: 33322962 [No Abstract] [Full Text] [Related]
9. Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. Lerman C; Schnoll RA; Hawk LW; Cinciripini P; George TP; Wileyto EP; Swan GE; Benowitz NL; Heitjan DF; Tyndale RF; Lancet Respir Med; 2015 Feb; 3(2):131-138. PubMed ID: 25588294 [TBL] [Abstract][Full Text] [Related]
11. Nicotine metabolite ratio and smoking outcomes using nicotine replacement therapy and varenicline among smokers with and without psychiatric illness. Clyde M; Pipe A; Els C; Reid R; Fu A; Clark A; Tulloch H J Psychopharmacol; 2018 Sep; 32(9):979-985. PubMed ID: 29788791 [TBL] [Abstract][Full Text] [Related]
12. Searching for Personalized Medicine for Binge Drinking Smokers: Smoking Cessation Using Varenicline, Nicotine Patch, or Combination Nicotine Replacement Therapy. Kaye JT; Johnson AL; Baker TB; Piper ME; Cook JW J Stud Alcohol Drugs; 2020 Jul; 81(4):426-435. PubMed ID: 32800078 [TBL] [Abstract][Full Text] [Related]
13. Does menthol cigarette use moderate the effect of nicotine metabolism on short-term smoking cessation? Jao NC; Veluz-Wilkins AK; Smith MJ; Carroll AJ; Blazekovic S; Leone FT; Tyndale RF; Schnoll RA; Hitsman B Exp Clin Psychopharmacol; 2017 Jun; 25(3):216-222. PubMed ID: 28493744 [TBL] [Abstract][Full Text] [Related]
14. Precision nicotine metabolism-informed care for smoking cessation in Crohn's disease: A pilot study. Scoville EA; Tindle HA; Wells QS; Peyton SC; Gurwara S; Pointer SO; Horst SN; Schwartz DA; Adams DW; Freiberg MS; Gatskie V; King S; Abney LR; Beaulieu DB PLoS One; 2020; 15(3):e0230656. PubMed ID: 32214373 [TBL] [Abstract][Full Text] [Related]
15. Smoking cessation medicines and e-cigarettes: a systematic review, network meta-analysis and cost-effectiveness analysis. Thomas KH; Dalili MN; López-López JA; Keeney E; Phillippo D; Munafò MR; Stevenson M; Caldwell DM; Welton NJ Health Technol Assess; 2021 Oct; 25(59):1-224. PubMed ID: 34668482 [TBL] [Abstract][Full Text] [Related]
16. Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers. Schuit E; Panagiotou OA; Munafò MR; Bennett DA; Bergen AW; David SP Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011823. PubMed ID: 28884473 [TBL] [Abstract][Full Text] [Related]
17. Metabotropic glutamate receptor 5 as a potential target for smoking cessation. Chiamulera C; Marzo CM; Balfour DJK Psychopharmacology (Berl); 2017 May; 234(9-10):1357-1370. PubMed ID: 27847973 [TBL] [Abstract][Full Text] [Related]
18. Known and novel sources of variability in the nicotine metabolite ratio in a large sample of treatment-seeking smokers. Chenoweth MJ; Novalen M; Hawk LW; Schnoll RA; George TP; Cinciripini PM; Lerman C; Tyndale RF Cancer Epidemiol Biomarkers Prev; 2014 Sep; 23(9):1773-82. PubMed ID: 25012994 [TBL] [Abstract][Full Text] [Related]
19. Associations Between Nicotine Metabolite Ratio and Gender With Transitions in Cigarette Smoking Status and E-Cigarette Use: Findings Across Waves 1 and 2 of the Population Assessment of Tobacco and Health (PATH) Study. Verplaetse TL; Peltier MR; Roberts W; Moore KE; Pittman BP; McKee SA Nicotine Tob Res; 2020 Jul; 22(8):1316-1321. PubMed ID: 32152625 [TBL] [Abstract][Full Text] [Related]
20. A review of the efficacy of smoking-cessation pharmacotherapies in nonwhite populations. Robles GI; Singh-Franco D; Ghin HL Clin Ther; 2008 May; 30(5):800-12. PubMed ID: 18555928 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]